RxDoctor Payments Data

Michael Waxman, MD

Emergency Medicine · Providence, RINPI 1518904481

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $73,421 of the $73,697 with a category attached, or 99.6%. Gilead accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $27,485 and has fallen 99.3% since, to $184 in 2023. Among emergency medicine clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$73,697in general payments, 2019–2025

Across 11 payments — averaging $6699.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$74K
  • Vapotherm Inc$41
$90,649in research payments, 2019–2025

Across 10 payments — averaging $9064.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gen-probe, Inc.$91K

What the payments were for

  • Consulting fees$73,421100%
  • Food & beverage$2760%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead10$73,657
Vapotherm Inc1$41

How this compares

$73,697 in reported general payments places this provider in the 95th percentile of 286 emergency medicine providers in Rhode Island.

See all emergency medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$13,517
Medicare patients
91
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl18$4,944

Paid to pharmacies, not to this prescriber.

Other emergency medicine in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →